2024

Kupcova K, Senavova J, Jura F, Herman V, Rajmonova A, Pacheco-Blanco M,Chrbolkova T, Hamova I, Davis RE, Havranek O. Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma. Exp Hematol Oncol. 2024 Nov 1;13(1):108. doi: 10.1186/s40164-024-00568-6. (IF 9.4, D1) [PubMed]

Bettazova N, Senavova J, Kupcova K, Sovilj D, Rajmonova A, Andera L, Svobodova K, Berkova A, Zemanova Z, Daumova L, Herman V, Dolníkova A, Davis RE, Trneny M, Klener P, Havranek O. Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies. Blood Adv. 2024 Oct 22;8(20):5279-5289. doi: 10.1182/bloodadvances.2024013205.  [PubMed] (IF 7.4, Q1)

Eken JA, Koning MT, Kupcova K, Sepúlveda Yáñez JH, de Groen RAL, Quinten E, Janssen J, van Bergen CAM, Vermaat JSP, Cleven A, Navarrete MA, Ylstra B, de Jong D, Havranek O, Jumaa H, Veelken H. Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. J Exp Med. 2024 May 6;221(5):e20230941. doi: 10.1084/jem.20230941.[PubMed] (IF 12.8)

Zemankova P, Cerna M, Horackova K, Ernst C, Soukupova J, Borecka M, Blümcke B, Cerna L, Cerna M, Curtisova V, Dolezalova T, Duskova P, Dvorakova L, Foretova L, Havranek O, Hauke J, Hahnen E, Hodulova M, Hovhannisyan M, Hruskova L, Janatova M, Janikova M, Jelinkova S, Just P, Kosarova M, Koudova M, Krutilkova V, Machackova E, Matejkova K, Michalovska R, Misove A, Nehasil P, Nemcova B, Novotny J, Panczak A, Pesek P, Scheinost O, Springer D, Stastna B, Stranecky V, Subrt I, Tavandzis S, Tureckova E, Vesela K, Vlckova Z, Vocka M, Wappenschmidt B, Zima T, Kleibl Z, Kleiblova P. A deep intronic recurrent CHEK2 variant c.1009-118_1009-87delinsC affects pre-mRNA splicing and contributes to hereditary breast cancer predisposition. Breast. 2024 Mar 25;75:103721. doi: 10.1016/j.breast.2024.103721.[PubMed] (IF 5.7)

Malarikova D, Jorda R, Kupcova K, Senavova J, Dolnikova A, Pokorna E, Kazantsev D, Nozickova K, Sovilj D, Bellanger C, Chiron D, Andera L, Krystof V, Strnad M, Helman K, Klanova M, Trneny M, Havranek O, Klener P. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion. Exp Hematol Oncol. 2024 Mar 25;13(1):34. doi: 10.1186/s40164-024-00499-2.[PubMed] (IF 9.4, Q1)

Tkachenko A, Kupcova K, Havranek O. B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells. Int. J. Mol. Sci. 2024, 25, 10. [PubMed] (IF 4.9, Q1)

Zlatar L, Knopf J, Singh J, Wang H, Muñoz-Becerra M, Herrmann I, Chukwuanukwu RC, Eckstein M, Eichhorn P, Rieker RJ, Naschberger E, Burkovski A, Krenn V, Bilyy R, Butova T, Liskina I, Kalabukha I, Khmel O, Boettcher M, Schett G, Butov D, Tkachenko A, Herrmann M. Neutrophil extracellular traps characterize caseating granulomas. Cell Death Dis. 2024 Jul 31;15(7):548. doi: 10.1038/s41419-024-06892-3. [PubMed] (IF 8.1, Q1)

Tkachenko A. Apoptosis and eryptosis: similarities and differences. Apoptosis. 2024 Apr;29(3-4):482-502. doi: 10.1007/s10495-023-01915-4. [PubMed] (IF 6.1, Q1)

Soukupova J, Stastna B, Kanwal M, Hojny J, Zemankova P, Borecka M, Cerna L, Cerna M, Cerna M, Curtisova V, Dolezalova T, Duskova P, Foretova L, Havranek O, Horackova K, Hovhannisyan M, Hruskova L, Chvojka S, Janatova M, Janikova M, Jelinkova S, Just P, Kalousova M, Kleiblova P, Kosarova M, Koudova M, Kral J, Krausova M, Krutilkova V, Machackova E, Matejkova K, Michalovska R, Nehasil P, Nemcova B, Novotny J, Palek M, Pesek P, Safarikova M, Scheinost O, Springer D, Stolarova L, Stranecky V, Subrt I, Tavandzis S, Tureckova E, Vesela K, Vlckova Z, Vocka M, Zima T, Macurek L, Kleibl Z; CZECANCA consortium. A comprehensive study evaluating germline FANCG variants in predisposition to breast and ovarian cancer. Cancer Med. 2024 Aug;13(16):e70103. doi: 10.1002/cam4.70103. [PubMed] (IF 2.9, Q2)

Prokopiuk, V., Onishchenko, A., Pazura, Y., Bespalova, I., Kökbaş, U., Tryfonyuk, L., Mateychenko, P., Kot, K., Kurmangaliyeva, S., Kot, Y., Yefimova, S., & Tkachenko, A. (2024). Nanostructured zinc carbonate hydroxide microflakes: assessing the toxicity against erythrocytes and L929 cellsin vitro. Nanotechnology, 36(8), 10.1088/1361-6528/ad9aac. https://doi.org/10.1088/1361-6528/ad9aac. (IF 2.9, Q3) [PubMed]

Seňavová, J., Rajmonová, A., Heřman, V., Jura, F., Veľasová, A., Hamová, I., Tkachenko, A., Kupcová, K., & Havránek, O. (2024). Immune Checkpoints and Their Inhibition in T-Cell Lymphomas. Folia biologica, 70(3), 123–151. https://doi.org/10.14712/fb2024070030123. [PubMed] (IF 1.1, Q3)

Tkachenko A, Havranek O. Erythronecroptosis: an overview of necroptosis or programmed necrosis in red blood cells. Molecular and cellular biochemistry, 479(12), 3273–3291. https://doi.org/10.1007/s11010-024-04948-8. [PubMed] (IF 3.5, Q3)

Kot, Y., Klochkov, V., Prokopiuk, V., Sedyh, O., Tryfonyuk, L., Grygorova, G., Karpenko, N., Tomchuk, O., Kot, K., Onishchenko, A., Yefimova, S., & Tkachenko, A. (2024). GdVO₄:Eu³⁺ and LaVO₄:Eu³⁺ Nanoparticles Exacerbate Oxidative Stress in L929 Cells: Potential Implications for Cancer Therapy. International Journal of Molecular Sciences, 25(21), 11687. https://doi.org/10.3390/ijms252111687. [PubMed] (IF 4.9, Q1)

Tkachenko A.Hemocompatibility studies in nanotoxicology: Hemolysis or eryptosis? (A review). Toxicology in vitro : an international journal published in association with BIBRA, 98, 105814. https://doi.org/10.1016/j.tiv.2024.105814 [PubMed] (IF 2.6, Q3)

Zefiova S, Kireev V, Bespalova I, Kovok N, Prokopiuk V, Tkachenko A, Demchenko L, Tomchuk O. Effect of TiO2 Nanoparticles Defect Structure on their ROS Scavenging Ability. 2024 IEEE 14th International Conference, 979-8-3503-8012-5/24. (IF N/A)

Novotný J, Cibula D, Curtisová V, Dubová O, Foretová L, Germanová A, Janatová M, Havránek O, Hojsáková M, Hudcová M, Koudová M, Krutílková V, Palácová M, Paulich S, Petráková K, Presl J, Puchmajerová A, Soukupová J, Šenkeříková M, Šimková Z, Štěpánková H, Šubrt I, Tachecí I, Tesner P, Urban O, Veselá K, Vilímová Š, Vlčková Z, Vočka M, Weinberger V, Zikán M, Zimovjanová M, Kleibl Z, Kleiblová P. The guidelines for clinical practice for carriers of germline mutations in the Lynch syndrome predisposition genes MLH1, MSH2, MSH6, PMS2 and large deletions of EPCAM (4.2024). Klin Onkol 2024;37(5);384-389. doi: 10.48095/ccko2024384. [Link]

2023

Tkachenko A, Havranek O. Redox Status of Erythrocytes as an Important Factor in Eryptosis and Erythronecroptosis. Folia Biologica. 2023  [link] (IF 0.6, Q3)

Tkachenko, A., Onishchenko, A. & Prokopiuk, V. Do Marine Polysaccharides Carrageenans Modulate Non-apoptotic Regulated Cell Deaths ? (a Review). Curr. Pharmacol. Rep. (2023). https://doi.org/10.1007/s40495-023-00339-7. [link] (IF N/A)

Tkachenko A, Onishchenko A, Myasoedov V, Yefimova S, Havranek O. Assessing regulated cell death modalities as an efficient tool for in vitro nanotoxicity screening: a review. Nanotoxicology. 2023 Apr 21:1-31. doi: 10.1080/17435390.2023.2203239. (IF 3.6, Q2) [PubMed]

Tkachenko A, Onishchenko A. Zincoptosis: does it exist? Apoptosis. 2023 Mar 24. doi: 10.1007/s10495-023-01836-2. (IF 6.1, Q1) [PubMed] 

Kral J, Jelinkova S, Zemankova P, Vocka M, Borecka M, Cerna L, Cerna M, Dostalek L, Duskova P, Foretova L, Havranek O, Horackova K, Hovhannisyan M, Chvojka S, Kalousova M, Kosarova M, Koudova M, Krutilkova V, Machackova E, Nehasil P, Novotny J, Otahalova B, Puchmajerova A, Safarikova M, Slama J, Stranecky V, Subrt I, Tavandzis S, Zikan M, Zima T, Soukupova J, Kleiblova P, Kleibl Z, Janatova M. Germline multigene panel testing of patients with endometrial cancer. Oncol Lett. 2023 Apr 12;25(6):216. doi: 10.3892/ol.2023.13802. (IF 2.9) [link]

2022

Klanova M, Kazantsev D, Pokorna E, Zikmund T, Karolova J, Behounek M, Renesova N, Sovilj D, Kelemen CD, Helman K, Jaksa R, Havranek O, Andera L, Trneny M, Klener P. Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas. Mol Cancer Ther. 2022 Jan;21(1):89-99. doi: 10.1158/1535-7163.MCT-21-0511. Epub 2021 Nov 2. (IF 6.011) [PubMed] 

Maco M, Kupcova K, Herman V, Ondeckova I, Kozak T, Mocikova H, Havranek O; Czech Hodgkin Lymphoma Study Group. Circulating tumor DNA in Hodgkin lymphoma. Ann Hematol. 2022 Sep 8. doi: 10.1007/s00277-022-04949-x. (IF 4.03) [PubMed] 

Henderson J, Havranek O, Ma MCJ, Herman V, Kupcova K, Chrbolkova T, Pacheco-Blanco M, Wang Z, Comer JM, Zal T, Davis RE. Detecting Förster resonance energy transfer in living cells by conventional and spectral flow cytometry. Cytometry A. 2022 Oct;101(10):818-834. doi: 10.1002/cyto.a.24472.  (IF 4.714) [PubMed] (H, I, 131)

2021

Herbrich S, Baran N, Cai T,et al. Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML.Journal for ImmunoTherapy of Cancer2021;9:e002968. doi:10.1136/jitc-2021-002968. (IF 12.485)

Szydłowski M, Garbicz F, Jabłońska E, Górniak P, Komar D, Pyrzyńska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Ciećkiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Gołas A, Domagała J, Winiarska M, Graczyk-Jarzynka A, Białopiotrowicz E, Polak A, Barankiewicz J, Puła B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brzózka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczyński P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20. Antibodies. Cancer Res. 2021 Dec 1;81(23):6029-6043. doi: 10.1158/0008-5472.CAN-21-1023. (IF 13.312) [PubMed] 

Vockova P, Molinsky J, Klanova M, Karban J, Spacek M, Havranek O, Kupcova K, Kazantsev D, Trneny M, Klener P. CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement. Leuk Lymphoma. 2021 Apr;62(4):861-867. doi: 10.1080/10428194.2020.1849678. (IF 2.996) [PubMed] (N, H, 131)

2020

Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, Chrbolkova T, Khashab T, Chowhury SM, Sircar A, Shirazi F, Singh RK, Alinari L, Zhu J, Havranek O, Tsichlis P, Woyach J, Baiocchi R, Samaniego F, Sehgal L. Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020;4(18):4382-4392. doi:10.1182/bloodadvances.2020001685. (IF 6.799) [Pubmed] (I, H, 131)

2019

Kleiblová P, Stolařová L, Křížová K, Lhota F, Hojný J, Zemánková P, Havránek O, Vočka M, Černá M, Lhotová K, Borecká M, Janatová M, Soukupová J, Ševčík J, Zimovjanová M, Kotlas J, Panczak A, Veselá K, Červenková J, Schneiderová M, Burócziová M, Burdová K, Stránecký V, Foretová L, Macháčková E, Tavandzis S, Kmoch S, Macůrek L, Kleibl Z. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance. Klin Onkol. 2019 Summer;32(Supplementum2):36-50. doi: 10.14735/amko2019S36. [PubMed] (N, H, 131)

Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, Havranek O, Soukup J, Svobodova K, Zemanova Z, Tuskova D, Pokorna E, Helman K, Forsterova K, Pacheco-Blanco M, Vockova P, Berkova A, Fronkova E, Trneny M, Klener P. Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019 Apr 19. pii: clincanres.3275.2018. doi: 10.1158/1078-0432.CCR-18-3275. (IF 10.107) [PubMed] (H, 131)

Kleiblova P, Stolarova L, Krizova K, Lhota F, Hojny J, Zemankova P, Havranek O, Vocka M, Cerna M, Lhotova K, Borecka M, Janatova M, Soukupova J, Sevcik J, Zimovjanova M, Kotlas J, Panczak A, Vesela K, Cervenkova J, Schneiderova M, Burocziova M, Burdova K, Stranecky V, Foretova L, Machackova E, Tavandzis S, Kmoch S, Macurek L, Kleibl Z. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer. Int J Cancer. 2019 May 3. doi: 10.1002/ijc.32385. (IF 5.145) [PubMed] (N, H, 131)